Envestnet Portfolio Solutions’s Acadia Pharmaceuticals ACAD Stock Holding History

Envestnet Portfolio Solutions’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Buy	+23,593	New	+$519K	﹤0.01%	921

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Portfolio Solutions's ACAD Position: Q2 2026 in Review

Envestnet Portfolio Solutions opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 23,593 shares worth $597K. The stake represents ﹤0.01% of the portfolio and ranks #921 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Envestnet Portfolio Solutions held 23,593 shares of Acadia Pharmaceuticals worth $597K as of Q2 2026.
Acadia Pharmaceuticals was a new Envestnet Portfolio Solutions position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q2 2026, its #921 holding.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2026, filed 20 Jul 2026.